Semaglutide-Based Implant Agreement for Obesity Treatment from Vivani Medical and Novo Nordisk

Vivani Medical, an America Birleşik Devletleri-based biopharmaceutical company, has signed a significant agreement with the Danish giant Novo Nordisk…

NPM-139 stands out as an ultra-long-acting mini implant manufactured using vivani's proprietary NanoPortal™ technology and containing the active ingredient semaglutide. This new generation medical device aims…